

Special Issue

Innovations in Nanomedicine for Disease Management

Message from the Guest Editors

Nanomedicine represents a revolutionary frontier in disease management, leveraging the unique properties of nanoparticles to transform diagnostics, therapeutics and drug delivery systems. This Special Issue delves into cutting-edge advancements in nanotechnology that offer precise, targeted and efficient solutions for a broad spectrum of medical challenges. "Innovations in Nanomedicine for Disease Management" explores the applications of nanomedicine in early disease detection, personalized medicine and minimally invasive treatments. It covers breakthroughs in smart drug delivery systems, optimizing therapeutic outcomes while minimizing side effects. Additionally, this Special Issue highlights the integration of nanotechnology with emerging fields such as gene therapy, immunotherapy, and regenerative medicine, aiming to underscore the transformative potential of nanomedicine in enhancing patient care and revolutionizing contemporary healthcare practices. Researchers and practitioners are invited to contribute to these groundbreaking studies that pave the way for the next generation of disease management technologies.

Guest Editors

Dr. Anna Valentino

Research Institute on Terrestrial Ecosystems (IRET)—CNR, Via Pietro Castellino 111, 80131 Naples, Italy

Dr. Raffaele Conte

Research Institute on Terrestrial Ecosystems (IRET)—CNR, Via Pietro Castellino, 80131 Naples, Italy

Deadline for manuscript submissions

closed (28 February 2026)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/209113

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).